News
Resources
Blog
Sites
340B program remains second largest federal drug program, yet little solid evidence of benefits to patient
By Nicole Longo | June 30, 2022
Over the three decades since Congress created the 340B drug pricing program, we’ve seen massive growth in its size. As a program meant to serve vulnerable patients, this sounds great, right? The...
Read More
Copay assistance is a lifeline for patients. So why are insurers blocking it?
By Stephen J. Ubl | June 29, 2022
In today’s broken insurance system, patients too often pay more for a medicine than what their insurance company pays.
Read More
Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve
By Nicole Longo | June 24, 2022
Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas....
Read More
CMS coverage decision restricts access to treatments for Alzheimer’s disease
By Nicole Longo | June 22, 2022
This year’s Alzheimer’s and Brain Awareness Month offers an important opportunity to remember the severe toll that Alzheimer’s takes on patients and family caregivers. Unfortunately, this year also...
Read More
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
By Jackie McRae | June 16, 2022
A new report from Partnership for Health Analytic Research or PHAR describes how value assessments that use traditional cost-effectiveness analyses can overlook important health disparities and risk...
Read More
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
By Stami Williams | June 16, 2022
Patient concerns over ever-increasing costs are growing, especially when it comes to their health care. Morning Consult recently conducted a 50-state poll of 20,000 Americans on behalf of PhRMA to...
Read More
Key takeaways from ASCO's annual meeting
By Michael Ybarra | June 10, 2022
Last weekend, health care professionals, patients, scientists and biopharmaceutical researchers gathered for the American Society of Clinical Oncology's (ASCO) annual meeting. With over 200 sessions...
Read More
Recognizing LGBTQ+ Pride in biopharmaceutical science
By Andrew Powaleny | June 9, 2022
June is Pride Month and, like many across the country, we look forward to celebrating the importance of equality and reminding ourselves to continually seek opportunities to make our society more...
Read More
Biopharmaceutical researchers to discuss the value of R&D with Congress
By Stephen J. Ubl | June 9, 2022
Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in bringing new treatments...
Read More
New poll shows voters sounding the alarm on health insurance companies and PBMs
By Cynthia Hicks | June 6, 2022
Many Americans battle with an illness every day, but unfortunately for some, their illness is not the only battle they face. A recent Morning Consult/PhRMA poll of 2,004 registered voters shows that...
Read More
Potential gene therapies bring hope to patients with sickle cell disease
By Katie Koziara | June 6, 2022
A recent analysis highlights how potential gene therapies have the potential to dramatically reduce income disparities for patients with sickle cell disease, leading to as much as $21,000 more in...
Read More
The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
